Relation between microRNA‐21, transforming growth factor β and response to treatment among chronic hepatitis C patients
| Autor: | Hanan Mostafa, Salwa Tawfik, Ahmed Gaballah, Amany A. Ghazy, Eman M A Osman, Eman A. Rashwan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Pyrrolidines Daclatasvir Sofosbuvir Hepatitis C virus Serum albumin Hepacivirus medicine.disease_cause Antiviral Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Transforming Growth Factor beta Fibrosis Virology Ribavirin medicine Humans Prospective Studies 030212 general & internal medicine Prothrombin time medicine.diagnostic_test biology business.industry Imidazoles Valine Hepatitis C Chronic Middle Aged Viral Load medicine.disease MicroRNAs Treatment Outcome Infectious Diseases chemistry Immunology biology.protein Drug Therapy Combination Female 030211 gastroenterology & hepatology Carbamates business Viral load Biomarkers medicine.drug |
| Zdroj: | Journal of Medical Virology. 91:2166-2173 |
| ISSN: | 1096-9071 0146-6615 |
| Popis: | Background Persistence of hepatitis C virus (HCV) infection and response to antiviral therapy has been shown to be associated with inappropriate levels of cytokines and microRNAs (miRNAs). miRNA levels have been reported to fluctuate during treatment. Thus they could be useful predictors for responses to treatment among HCV infected patients, thereby reducing ineffective treatments. Aim The current study aimed to investigate the relation between miRNA-21 expression profiles, transforming growth factor β (TGF-β) serum levels and response to treatment with the new direct antiviral drugs (sofosbuvir + daclatasvir ± ribavirin), among HCV infected Egyptian patients. Subjects and methods This prospective study was conducted on 50 HCV infected patients (before and after treatment) and 20 healthy volunteers. miRNA expression profiles were determined by real-time polymerase chain reaction and TGF-β1 serum levels were measured by using enzyme-linked immunosorbent assay. Results There was a significant increase in serum albumin, platelets count and a significant decrease in liver enzymes, serum bilirubin, and prothrombin time after treatment. Significant reduction of viral load among HCV patients after receiving the treatment was reported. Concomitantly, there was an increase in the relative quantity of miRNA-21 (P = .001*) and serum levels of TGF-β1 ( P = .337) among HCV patients after receiving treatment. Conclusion Nearly all responders to direct antiviral drugs showed increased levels of both miRNA-21 and TGF-β1. This may indicate an interplay between TGF-β1 and miRNA-21 during remission or progression of viral infection. Thus miRNA-21 could be used as promising serum biomarker, for assessment of antiviral treatment efficacy and improvement of fibrosis among chronically infected HCV patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text